Markers for HCV-related HCC: plasma profiling, targeted strategies and validation
Markers for HCV-related HCC: plasma profiling, targeted strategies and validation
批准号:
7581400
负责人:
LAURA BERETTA
金额:
$36.52万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-01 至 2014-02-28
关键词:
3-DimensionalAgeAlbuminsBindingBiologicalBiological MarkersCirrhosisClinicalComplexDevelopmentDiagnosisDiagnosticDiseaseDisease ProgressionEarly DiagnosisEnzyme-Linked Immunosorbent AssayEtiologyFibrosisFractionationGenderGene ProteinsHepatitis CHepatitis C virusHigh PrevalenceHumanIndividualIsotope LabelingLeadLengthLiverLiver CirrhosisLiver diseasesMass Spectrum AnalysisMeasuresMethodsMolecular WeightPatientsPatternPlasmaPlasma ProteinsPopulationPrimary carcinoma of the liver cellsProtein BindingProtein FragmentProtein IsoformsProteinsProteomeProteomicsReportingResearchResearch DesignResearch PersonnelSamplingScanningSensitivity and SpecificitySerumSpecimenStagingTechnologyTherapeuticTissuesValidationassay developmentbasechemokine receptorcohortcytokineinsightprotein expressionprotein transportpublic health relevancetrend
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A trend of increasing rates of hepatocellular carcinoma (HCC) has been reported worldwide, that is related to the high prevalence of hepatitis C virus (HCV) infection in the population. Better means for HCC diagnosis are urgently needed. Our prior studies provided evidence for an association between the etiology of the underlying liver disease and differences in patterns of gene/protein expression in HCC. They also offered new insights into protein isoforms that are potentially important in the development of HCC. We recently developed a method to comprehensively and quantitatively profile the proteome of a complex sample and we have applied this method to the liver and to plasma. This method, based on extensive fractionation of intact proteins, resulted in the identification of approximately 9,000 proteins in the liver, identified with high confidence and including low-abundance proteins such as cytokines, chemokines and receptors. An abundance score based on spectral counts was attributed to each identified protein. The calculated abundance scores appeared to be a good estimate of protein abundance. In the plasma, numerous low-abundance proteins in the biomarker concentration range (pg/ml) were identified and proteins specific to disease stage (fibrosis and early HCC) were identified in liver tissue as well as in plasma. Interestingly, there was no correlation between the abundance changes observed in the tissues and the abundance changes observed in the plasma for selective proteins changing with disease stage. In conclusion, this method reached a depth in proteomic profiling not previously reported for complex biological mixtures such as mammalian tissue and plasma, allowed for the identification of protein changes associated with disease and suggested that tissue-based discovery and plasma-based discovery studies may lead to different results. The purpose of this proposal is to utilize this method for the identification of protein biomarkers for HCV-related HCC that could be used for early detection and diagnosis. We will apply this approach to identify proteins and their isoforms that differ in expression levels between plasma obtained from patients with HCV-related cirrhosis that have recently progressed to HCC and patients with HCV-related cirrhosis with no HCC. The most promising candidates identified in the discovery component of this research will be targeted for validation. We will establish the sensitivity and specificity of these protein biomarkers individually and in combination, for detecting HCC early. PUBLIC HEALTH RELEVANCE: A trend of increasing rates of hepatocellular carcinoma (HCC) has been reported worldwide, that is related to the high prevalence of hepatitis C virus (HCV) infection in the population. Better means for HCC diagnosis are urgently needed. The purpose of this proposal is the development of a robust set of biomarkers for HCC that could be used for early detection and diagnosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Core
-
批准号:10480072
-
项目类别:
-
资助金额:$28.3万
-
财政年份:2019
-
负责人:LAURA BERETTA
-
依托单位:
Administrative Core
-
批准号:10246493
-
项目类别:
-
资助金额:$29.04万
-
财政年份:2019
-
负责人:LAURA BERETTA
-
依托单位:
Administrative Core
-
批准号:10687032
-
项目类别:
-
资助金额:$28.3万
-
财政年份:2019
-
负责人:LAURA BERETTA
-
依托单位:
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma
-
批准号:10687031
-
项目类别:
-
资助金额:$220.67万
-
财政年份:2019
-
负责人:LAURA BERETTA
-
依托单位:
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma
-
批准号:10480071
-
项目类别:
-
资助金额:$227.83万
-
财政年份:2019
-
负责人:LAURA BERETTA
-
依托单位:
Project 3: Non-invasive assessment of liver fibrosis stage and progression in obesity and diabetes: a Hispanic population study
-
批准号:10687043
-
项目类别:
-
资助金额:$102.38万
-
财政年份:2019
-
负责人:LAURA BERETTA
-
依托单位:
Project 3: Non-invasive assessment of liver fibrosis stage and progression in obesity and diabetes: a Hispanic population study
-
批准号:10246499
-
项目类别:
-
资助金额:$67.15万
-
财政年份:2019
-
负责人:LAURA BERETTA
-
依托单位:
Project 3: Non-invasive assessment of liver fibrosis stage and progression in obesity and diabetes: a Hispanic population study
-
批准号:10024079
-
项目类别:
-
资助金额:$57.52万
-
财政年份:2019
-
负责人:LAURA BERETTA
-
依托单位:
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma
-
批准号:10024063
-
项目类别:
-
资助金额:$233.21万
-
财政年份:2019
-
负责人:LAURA BERETTA
-
依托单位:
Project 3: Non-invasive assessment of liver fibrosis stage and progression in obesity and diabetes: a Hispanic population study
-
批准号:10480101
-
项目类别:
-
资助金额:$55.19万
-
财政年份:2019
-
负责人:LAURA BERETTA
-
依托单位:
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma
-
批准号:10246492
-
项目类别:
-
资助金额:$215.62万
-
财政年份:2019
-
负责人:LAURA BERETTA
-
依托单位:
Administrative Core
-
批准号:10024071
-
项目类别:
-
资助金额:$81.85万
-
财政年份:2019
-
负责人:LAURA BERETTA
-
依托单位:
Genomics of HCC in the Hispanic population of Texas
-
批准号:10370304
-
项目类别:
-
资助金额:$35.35万
-
财政年份:2018
-
负责人:LAURA BERETTA
-
依托单位:
Early Detection of Hepatocellular Carcinoma
-
批准号:9109275
-
项目类别:
-
资助金额:$64.54万
-
财政年份:2016
-
负责人:LAURA BERETTA
-
依托单位:
Early Detection of Hepatocellular Carcinoma
-
批准号:9926812
-
项目类别:
-
资助金额:$64.42万
-
财政年份:2016
-
负责人:LAURA BERETTA
-
依托单位:
Early Detection of Hepatocellular Carcinoma
-
批准号:10448178
-
项目类别:
-
资助金额:$69.43万
-
财政年份:2016
-
负责人:LAURA BERETTA
-
依托单位:
Early Detection of Hepatocellular Carcinoma
-
批准号:10612468
-
项目类别:
-
资助金额:$65.0万
-
财政年份:2016
-
负责人:LAURA BERETTA
-
依托单位:
Novel markers for HCV-related HCC
-
批准号:7994250
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2010
-
负责人:LAURA BERETTA
-
依托单位:
Novel markers for HCV-related HCC
-
批准号:7849419
-
项目类别:
-
资助金额:$3.45万
-
财政年份:2009
-
负责人:LAURA BERETTA
-
依托单位:
Markers for HCV-related HCC: plasma profiling, targeted strategies and validation
-
批准号:7813866
-
项目类别:
-
资助金额:$36.52万
-
财政年份:2009
-
负责人:LAURA BERETTA
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: